Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
30.94 USD | -4.83% | -2.95% | +132.63% |
May. 23 | Dyne Therapeutics Insider Sold Shares Worth $1,002,751, According to a Recent SEC Filing | MT |
May. 22 | Dyne Therapeutics Prices $325.5 Million Common Stock Offering | MT |
Business Summary
Number of employees: 143
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Rick Scalzo
DFI | Director of Finance/CFO | 38 | 19-11-30 |
John Najim
CTO | Chief Tech/Sci/R&D Officer | 48 | 19-07-31 |
Chief Tech/Sci/R&D Officer | 63 | 20-01-26 | |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 | |
Wildon Farwell
CTO | Chief Tech/Sci/R&D Officer | 49 | 21-03-03 |
Ashish Dugar
CTO | Chief Tech/Sci/R&D Officer | - | 21-02-07 |
Susanna High
COO | Chief Operating Officer | 56 | 20-06-30 |
Amy Reilly
IRC | Investor Relations Contact | 51 | 20-06-30 |
Daniel Wilson
LAW | General Counsel | 53 | 20-05-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Edward Hurwitz
BRD | Director/Board Member | 60 | 18-10-31 |
David Lubner
BRD | Director/Board Member | 60 | 20-02-29 |
Dirk Kersten
BRD | Director/Board Member | 49 | 18-10-31 |
Jason Rhodes
FOU | Founder | 54 | 17-11-30 |
Carlo Incerti
BRD | Director/Board Member | 65 | 22-03-01 |
Chief Tech/Sci/R&D Officer | 61 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 97,589,649 | 97,120,717 ( 99.52 %) | 0 | 99.52 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+132.63% | 3.07B | |
+51.85% | 57.87B | |
+41.48% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- DYN Stock
- Company Dyne Therapeutics, Inc.